Trials / Recruiting
RecruitingNCT06544720
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- The Affiliated Hospital of Qingdao University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Conditions
- Human Papillomavirus Associated Carcinomas
- Cervical Cancer
- Head and Neck Cancers
- Anal Cancer
- Vulva Cancer
- Vaginal Cancer
- Penile Cancer
- HPV-Related Malignancy
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SCG142 TCR-T cells | Monotherapy of SCG142 |
Timeline
- Start date
- 2023-08-02
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2024-08-09
- Last updated
- 2024-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06544720. Inclusion in this directory is not an endorsement.